Insomnia Therapeutics Market Report 2026

The insomnia therapeutics market size has grown strongly in recent years. It will grow from $3.2 billion in 2025 to $3.38 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising prevalence of sleep disorders, increased stress and lifestyle-related insomnia, widespread use of prescription sleep aids, expansion of retail pharmacy access, growing awareness of sleep health.

The insomnia therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.19 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growth in digital sleep therapeutics, increasing preference for non-pharmacological treatments, rising aging population, growing adoption of wearable sleep devices, expansion of telehealth-based insomnia management. Major trends in the forecast period include growing adoption of cognitive behavioral therapy for insomnia, rising demand for non-habit-forming sleep medications, increasing use of orexin receptor antagonists, expansion of home-based sleep therapy solutions, growing integration of sleep tracking with treatment plans.

The rising stress levels and lifestyle changes are expected to drive the growth of the insomnia therapeutics market in the coming years. Stress and lifestyle changes encompass the psychological and behavioral shifts in daily routines and responsibilities that lead to emotional strain and disrupted sleep patterns. The increase in stress is fueled by constant digital connectivity, which blurs work-life boundaries and reduces opportunities for true mental rest. Insomnia therapeutics play a key role by providing effective, evidence-based treatments that help restore healthy sleep patterns, alleviate sleep-related anxiety, and support mental well-being in the face of modern stressors. For example, in May 2024, according to the American Psychiatric Association (APA), a US-based organization of psychiatrists, the proportion of U.S. adults reporting heightened anxiety rose from 32% in 2022 to 37% in 2023 and reached 43% in 2024. Consequently, increasing stress levels and lifestyle changes are contributing to the expansion of the insomnia therapeutics market.

Major companies in the insomnia therapeutics market are concentrating on developing advanced treatments, such as dual orexin receptor antagonists (DORAs), to offer targeted therapies with fewer side effects and enhanced safety profiles. Dual orexin receptor antagonists are medications that block both orexin-1 and orexin-2 receptors in the brain, promoting sleep by inhibiting the wakefulness signaling pathway, and are commonly used to treat insomnia. For example, in June 2023, Idorsia Pharmaceuticals Ltd., a Switzerland-based pharmaceutical company, launched QUVIVIQ (daridorexant), a first-in-class DORA for the treatment of chronic insomnia disorder. This therapy is designed to reduce nighttime wakefulness without disrupting natural sleep architecture, providing patients with improved sleep onset, maintenance, and daytime functioning. Its approval represents a significant advancement in insomnia care, offering a targeted mechanism of action distinct from traditional sedative-hypnotics and addressing the need for long-term, non-habit-forming treatment options.

In May 2023, Nox Health, a U.S.-based provider of sleep diagnostics and value-based sleep care management services, acquired Somryst for $3.9 million. Through this acquisition, Nox Health sought to enhance its insomnia care offerings by incorporating the only FDA-cleared prescription digital therapeutic for chronic insomnia into its sleep management platform. Somryst is a U.S.-based digital therapeutic that provides cognitive behavioral therapy for adults suffering from chronic insomnia.

Major companies operating in the insomnia therapeutics market are Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Eisai Co. Ltd., Sumitomo Pharma Co. Ltd., Astellas Pharma Inc., Acadia Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Idorsia Ltd., Minerva Neurosciences, Neurim Pharmaceuticals Ltd., Big Health, Cerêve Inc., Innovative Neurological Devices, Neurovalens, Electromedical Products International Inc., Pear Therapeutics, ResMed Inc.

North America was the largest region in the insomnia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the insomnia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insomnia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the insomnia therapeutics market by increasing costs of imported pharmaceutical ingredients, medical devices, and digital sleep therapy hardware. These impacts are most visible in drug-based therapies and sleep monitoring devices, particularly across North America, Europe, and Asia-Pacific regions. Higher tariffs have contributed to pricing pressure in hospital and retail pharmacy channels. Conversely, tariffs have supported local drug manufacturing and encouraged regional development of sleep therapy devices and digital solutions.

The insomnia therapeutics market research report is one of a series of new reports that provides insomnia therapeutics market statistics, including insomnia therapeutics industry global market size, regional shares, competitors with a insomnia therapeutics market share, detailed insomnia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the insomnia therapeutics industry. This insomnia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Insomnia therapeutics encompass treatments designed to manage and relieve the symptoms of insomnia, a condition marked by difficulty in falling or staying asleep. These treatments include prescription medications, over-the-counter sleep aids, and non-drug approaches such as cognitive behavioral therapy for insomnia (CBT-I).

The primary treatment types in insomnia therapeutics are drugs and medical devices. Drugs for insomnia are pharmacological agents specifically developed to address sleep disorders by improving sleep initiation, maintenance, or overall sleep quality through mechanisms that regulate the sleep-wake cycle. They are available in various formulations, including tablets, capsules, liquid solutions, and patches, and can be administered via multiple routes such as oral, intravenous, transdermal, and others. Distribution occurs through hospital pharmacies, retail pharmacies, online pharmacies, clinics, and wellness centers.

The insomnia therapeutics market consists of sales of herbal sleep aids, wearable sleep devices, sleep-enhancing audio devices, aromatherapy products, smart mattresses, sleep masks with embedded technology, blue light-blocking glasses, and biofeedback devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.